Associated Papers
Evaluation of urinary cfDNA workflows for the molecular profiling of malignant disease.
Eberhard A et al.
Iscience, 2025
41142998 (PubMed )
Supplement: mmc5.xlsx › Table_S4
Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting.
Hilhorst R et al.
Cancers, 2023
37760447 (PubMed )
Supplement: cancers-15-04477-s001.zip › cancers-2436906-supplementary_tables.pdf
The combination of camrelizumab and apatinib obtained ongoing partial remission for a patient with osimertinib-resistant non-small cell lung cancer: case report.
Cong X et al.
Annals of Palliative Medicine, 2021
MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.
Chu LP et al.
The Oncologist, 2019
Impact of Mutation Density and Heterogeneity on Papillary Thyroid Cancer Clinical Features and Remission Probability.
Colombo C et al.
Thyroid : Official Journal of the American Thyroid Association, 2019
Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.
Ofner R et al.
Journal of Cancer Research and Clinical Oncology, 2017
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
Lee J et al.
Oncotarget, 2015
26375439 (PubMed )
Supplement: oncotarget-06-28211-s003.xlsx › Cosmic_MET
Select a paper to view details